Tuesday, October 27, 2015

Costs for Dementia Care Far Exceeding Other Diseases, Study Finds - The New York Times

Three diseases, leading killers of Americans, often involve long periods of decline before death. Two of them — heart disease and cancer — usually require expensive drugs, surgeries and hospitalizations. The third, dementia, has no effective treatments to slow its course.
So when a group of researchers asked which of these diseases involved the greatest health care costs in the last five years of life, the answer they found might seem surprising. The most expensive, by far, was dementia.
The study looked at patients on Medicare. The average total cost of care for a person with dementia over those five years was $287,038. For a patient who died of heart disease it was $175,136. For a cancer patient it was $173,383. Medicare paid almost the same amount for patients with each of those diseases — close to $100,000 — but dementia patients had many more expenses that were not covered.



On average, the out-of-pocket cost for a patient with dementia was $61,522 — more than 80 percent higher than the cost for someone with heart disease or cancer. The reason is that dementia patients need caregivers to watch them, help with basic activities like eating, dressing and bathing, and provide constant supervision to make sure they do not wander off or harm themselves. None of those costs were covered by Medicare.

Photo

John Rakis visiting Naomi Wallace, his mother-in-law. Mr. Rakis spent more than $189,000 in less than two years for caregivers and other expenses.CreditSam Hodgson for The New York Times

For many families, the cost of caring for a dementia patient often “consumed almost their entire household wealth,” said Dr. Amy S. Kelley, a geriatrician at Icahn School of Medicine at Mt. Sinai in New York and the lead author of the paper published on Monday in the Annals of Internal Medicine.
“It’s stunning that people who start out with the least end up with even less,” said Dr. Kenneth Covinsky, a geriatrician at the University of California in San Francisco. “It’s scary. And they haven’t even counted some of the costs, like the daughter who gave up time from work and is losing part of her retirement and her children’s college fund.”
Dr. Diane E. Meier, a professor of geriatrics and palliative care at Mount Sinai Hospital, said most families are unprepared for the financial burden of dementia, assuming Medicare will pick up most costs.
“What patients and their families don’t realize is that they are on their own,” Dr. Meier said.


Everything gets complicated when a person has dementia, noted Dr. Christine K. Cassel, a geriatrician and chief executive of the National Quality Forum.
She described a familiar situation: If a dementia patient in a nursing home gets a fever, the staff members say, “I can’t handle it” and call 911, she said. The patient lands in the hospital. There, patients with dementia tend to have complications — they get delirious and confused, fall out of bed and break a bone, or they choke on their food. Medical costs soar.

Photo


Costs for Dementia Care Far Exceeding Other Diseases, Study Finds - The New York Times

Behavioral Medicine in your Community

If you are interested in improving care for homeless individuals or reducing the number of incarcerated people, watch these outstanding presentations




Assisted Outpatient Treatment: The Nevada County Experience from Treatment Advocacy Center on Vimeo.

How can you help in making this a reality ?

Pharmacies also to participate in Pay for Performance



Express Scripts- New Program to Contact and Predict Patients Who May Not Be Taking Their Medicine Based On Ingenix Algorithms–We Want the Revenue Please Don’t Stop - Medical Quack

Friday, October 23, 2015

Judge Bars DOJ From Interfering With Calif. Medical Marijuana Laws - California Healthline

On Monday, a federal court in California ruled that federal authorities cannot close medical marijuana dispensaries that operate within the boundaries of state law, Time reports (White, Time, 10/20).



Details of Case
At issue in the case was the Drug Enforcement Administration's interpretation of the Rohrabacher-Farr amendment to last year's federal government spending bill.
Under the amendment, which lists the states with medical marijuana laws, the Department of Justice cannot use federal funds to stop such states from implementing their own laws to "authorize the use, distribution, possession or cultivation of medical marijuana" (Ingraham, "Wonkblog,"Washington Post, 10/20). However, DOJ interpreted the amendment to mean they were only barred from taking action against the state, not medical marijuana-related businesses and individuals who deal with the implementation of such laws, according to a leaked memo.
According to Time, DEA's enforcement resulted in the closure of many California dispensaries.

Details of Ruling



In his decision, U.S. District Judge Charles Breyer ruled that DOJ cannot use federal money to interfere with state medical marijuana laws and practices (Time, 10/20).
Breyer said the federal government's interpretation of the amendment "defies language and logic" and was "at odds with fundamental notions of the rule of law."
The decision could affect DEA's ability to prosecute future federal medical marijuana cases ("Wonkblog," Washington Post, 10/20).




Judge Bars DOJ From Interfering With Calif. Medical Marijuana Laws - California Healthline

Thursday, October 22, 2015

Fear itself | The Economist

PTSD   A term which has become common amongst military and veterans returning from Middle East assignment and former Vietnames and Korean War Veterans.

A mental illness caused by trauma may be one of the first to be understood in physical terms




PTSD, originally recognized during and after WWII as 'battle fatigue" It labels a constellation of signs and symptoms which have been studied with modern neuroscience.

Accounts of debilitating fear after trauma date back to the Trojan wars. In the 19th century survivors of train crashes were diagnosed with “railway spine” because doctors thought their hysteria was caused by compression of the backbone. In the first world war it was known as shell shock, soldier’s heart or battle fatigue. Not until soldiers returned from the Vietnam war with the same symptoms of hyper-vigilance, flashbacks and nightmares was the disorder truly taken seriously. In 1980 an umbrella term was coined: post-traumatic stress disorder (PTSD).
Attitudes are now quite different from those that prevailed during the second world war, when George Patton, an American general, threatened to court-martial men with battle fatigue. And research is progressing swiftly. A remarkable amount has been discovered about the causes of PTSD and how to treat it—which is welcome, because another discovery is how common it is.
 According to Charles Marmar, a psychiatrist at New York University’s medical centre, it may be the first psychiatric disorder “where we crack the mind-brain connections”.
Neural research is helping to reveal how people get stuck in a state of fear. The amygdalae, a pair of almond-sized regions deep in the brain, are the main orchestrators of fear, reading incoming signals such as smells and sounds and sending messages to other bits of the brain, which filter the signals before reacting. In someone with PTSD the filters struggle to distinguish between real threats and those that can safely be ignored.
The brain of a healthy person given cause to panic will tell the body to activate various reactions, including releasing adrenalin. A person’s heart rate will increase and they will have a strong urge to fight or flee. Once back to safety, symptoms subside and all that remains is a bad memory. A woman assaulted in a noisy bar may react fearfully to the sound of clinking glasses for a few weeks, but over time, in what is called “fear extinction”, the positive association of celebrating with friends will outweigh negative ones. The more often people receive such reminders without suffering a disaster, the more likely the fear is to dissipate—which is why it is important not to hide away after a trauma.  
Retraining the brain
When this mechanism fails, the result is PTSD. A soldier returning from war may continue to freeze and have debilitating flashbacks when anything reminds him of combat. One ex-soldier tells of “freaking out” every time his wife baked: it turned out that the smell of almonds evoked Semtex, an explosive. People who were abused as children may suffer when it is dark, because such abuse often happens at night.
Studies of twins suggest that susceptibility to PTSD is about 30% genetic. Researchers in the new field of epigenetics—the study of how external factors influence the way the instructions written in genes are expressed in organisms—have produced some evidence to suggest that stress might be passed on to offspring.

An exciting recent development is the discovery of markers that show differences between the brains, genes and even blood of people with and without PTSD. When a sufferer sees a picture of a frightened face, the amygdala shows a heightened response. At the same time the prefrontal cortex, which regulates fear, is suppressed. Researchers are hot on the trail of chemicals that could indicate PTSD in a blood test, says Kerry Ressler, a molecular scientist and psychiatrist at McLean Hospital of Harvard Medical School.  
Treatments mostly aim to retrain the brain’s fear response. Many patients are given cognitive therapy, which teaches them to think differently about what happened and trains them to cope with triggers. Debra Kaysen of the University of Washington says severe symptoms recede in about four out of five patients following a dozen or so sessions. Other patients are given exposure therapy, in which they are confronted with the feared stimuli. Adults may be asked to describe a traumatic event in excruciating detail until it loses its potency; young children might play out what happened with toys. Virtual-reality simulations have been used on soldiers. One therapist compares the work to treating a burn victim: layer after layer.

Amit Etkin and colleagues at Stanford University are studying how the brain circuits that control fear can be tweaked with the aid of SSRIs (a class of drugs, some of which are used to treat depression or anxiety) and transcranial magnetic stimulation, in which an electromagnet held close to the scalp transmits magnetic pulses to the brain. They found that stimulating a part of the frontal lobe can reduce activity in the amygdalae, which could lessen the symptoms of PTSD. Within five years, thinks Dr Etkin, new therapies will be available, including applying brain stimulation or using drugs to enhance the effects of talk therapy. Better treatments for other anxiety disorders, which afflict a third of Americans, could follow.
Even if new treatments for PTSD take longer to develop than hoped, acceptance of PTSD’s inherently physical nature could encourage sufferers to seek help earlier. Rape victims in Dr Kaysen’s practice typically waited 20 years before turning to her; Dr Marmar has treated veterans of the second world war who had tried to cope with their nightmares for as long as 40 years.
In a freezer in Boston are 50 samples of brain tissue donated to the world’s first brain bank dedicated to the study of PTSD, set up by the Department of Veterans Affairs. More veterans and civilians, with and without the disorder, are filling in health questionnaires and pledging to donate brain tissue after death. Those who could not be healed themselves might help arm future generations against the same suffering, or perhaps, one day, help prevent it altogether.




Fear itself | The Economist

23andMe Launches New Health Tests, Navigates FDA Regulations - iHealthBeat

Consumer driven genomic testing joins consumer driven laboratory testing.

Both promise to reduce health care costs. But, will established laboratories oppose these efforts. The disruption will be massive.  The key issue is FDA approval and reliability of results.

The development pipeline may be altererd forever.

Elizabeth Holmes, CEO and owner of Theranos states that publishing basic research in peer reviewed journals takes too much  time and expensive delays.  She prefers subitting to the FDA directly.  But does the FDA have the manpower to establish reliability and repeatability of that data ?

Background on 23andMe

On Wednesday, genetic testing company 23andMe announced that it will provide customers with health information again, but in a more limited capacity because of continuing regulatory involvement from FDA, the New York Times reports.

23andMe Co-Founder and CEO Anne Wojcicki launched the company with investments from her then-husband Google Co-Founder Sergey Brin (Pollack,New York Times, 10/21). 23andMe launched its first genetic test, the Personal Genome Service, in 2007 (Humer/Steenhuysen, Reuters, 10/21). The company said its original $99 test could predict a likelihood of developing conditions such as:
  • Alzheimer's disease (Perrone, AP/Sacramento Bee, 10/21);
  • Breast and ovarian cancer;
  • Certain heart conditions (Reuters, 10/21); and
  • Parkinson's disease (AP/Sacramento Bee, 10/21).
However, FDA in 2013 ordered 23andMe to halt sales of the service because the tests had not received FDA approval (Reuters, 10/21). Since then, the company has used the genetic data it collected to fuel drug research and has focused on analyzing family history and ancestry, which is not FDA-regulated. More than one million people have used 23andMe's saliva-based test to learn about their genetic code (AP/Sacramento Bee, 10/21).

Details of 23andMe's New Testing Service

About eight months ago, FDA approved 23andMe's carrier screening test for Bloom Syndrome, a disorder that causes short stature and a predisposition to cancer. FDA then reclassified such carrier screening tests as Class II medical devices, meaning they no longer require premarket approval, which involves clinical trials. 
On Wednesday, 23andMe debuted a new $199 carrier screening test that can predict whether a person will pass on one of 36 conditions to a child, including:
  • Beta thalassemia;
  • Cystic fibrosis;
  • Sickle cell anemia; and
  • Tay-Sachs disease (Reuters, 10/21).
In addition, the test can predict non-medical traits, including:
  • Eye color;
  • Earwax composition (New York Times, 10/21);
  • Freckles;
  • Hair curliness; and
  • Lactose intolerance (Reuters, 10/21).
In addition, 23andMe still is working toward gaining FDA approval for personal tests predicting an individual's likelihood of developing specific diseases and how that individual might respond to specific drugs

23andMe Launches New Health Tests, Navigates FDA Regulations - iHealthBeat